Can strategies targeting cleaved MUC1 overcome resistance to trastuzumab?
Araki
Kazuhiro
K
Braman Family Breast Cancer Research Institute, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA.
Pegram
Mark
M
D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000503:physiopathology*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D005260:Female; D006801:Humans; D018396:Mucin-1 / Q000378:metabolism*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018396:Mucin-1; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C060192:MUC1 protein, human